Tenascin-C (TNC), a large hexameric extracellular glycoprotein, is a pleiotropic molecule with multiple domains binding to a variety of receptors mediating a wide range of cellular functions. We earlier reported that TNC induces epithelial-mesenchymal transition (EMT)-like change in breast cancer cells. In the present study, we clarified TNC receptor involvement in this process. Among integrins previously reported as TNC receptors, substantial expression of av, a2, b1 and b6 subunits was detected by quantitative PCR and immunoblotting in MCF-7 cells. Integrin b6 mRNA was remarkably upregulated by transforming growth factor (TGF)-b1 treatment, and protein expression was prominently increased by additional exposure to TNC. Immunofluorescent labeling demonstrated integrin avb6 accumulation in focal adhesions after TNC treatment, especially in combination with TGF-b1. The a2 and b1 subunits were mainly localized at cell-cell contacts, av being found near cell cluster surfaces. Immunoprecipitation showed increase in avb1 heterodimers, but not a2b1, after TNC treatment. Activated b1 subunits detected by an antibody against the Ca 2 þ -dependent epitope colocalized with av in focal adhesion complexes, associated with FAK phosphorylation at tyrosine 925. Neutralizing antibodies against av and b1 blocked EMT-like change caused by TNC alone. In addition, anti-av and combined treatment with anti-b1 and anti-avb6 inhibited TGF-b1/TNC-induced EMT, whereas either of these alone did not. Integrin subunits av, b1 and b6, but not a2, bound to TNC immobilized on agarose beads in a divalent cation-dependent manner. Treatments with neutralizing antibodies against b1 and avb6 reduced av subunit bound to the beads. Immunohistochemistry of these receptors in human breast cancer tissues demonstrated frequent expression of b6 subunits in cancer cells forming scattered nests localized in TNC-rich stroma. These findings provide direct evidence that binding of avb6 and avb1 integrins to TNC as their essential ligand induces EMT-like change in breast cancer cells.
INTRODUCTION
Tenascin-C (TNC) is an extracellular matrix glycoprotein formed by hexamers of 200-400 kDa subunits. Although expression of TNC is rare in normal adult tissues, high levels are observed in pathological states featuring tissue remodeling, such as inflammation, wound healing and cancer. [1] [2] [3] In breast cancer tissues, TNC also demonstrates upregulated production by both tumor and stromal cells. 4 Immunohistochemistry has shown TNC expression to be indicative of a poorer patient outcome in invasive ductal carcinoma cases. 5 Low expression levels of miR-335, allowing high TNC expression, are linked to lung metastasis by human breast cancer. 6 In a mouse model, TNC knockdown causes dramatic inhibition of lung metastasis and colonization by breast cancer cells. 7 In vitro studies have shown that TNC promotes proliferation and migration of cancer cells [8] [9] [10] [11] and increases their expression of matrix metalloproteinases. 11, 12 Epithelial-mesenchymal transition (EMT) is an important event in cancer progression associated with invasion and metastasis. 13, 14 A role for TNC in this process is also suggested by its frequent presence in invasive borders of cancer tissues and in microinvasive foci around intraductal components undergoing EMT. 9, [15] [16] [17] Our recent study demonstrated TNC immunolabelling to be more frequently observed in stroma in the periphery of tumors featuring scattered cancer nests than in more solid lesions. 18 We also reported that TNC addition to culture medium induces EMT-like change in human breast cancer MCF-7 cells, accompanied by SRC activation and focal adhesion kinase (FAK) phosphorylation. 18 It has been reported that EMT induced by elevated SRC activity is blocked by neutralizing antibodies against av or b1, suggesting a requirement for signaling through integrin adhesion complexes. 19 A requirement for av integrin subunits was also clarified in TNC-induced EMT, 18 but the involvement of TNC receptors was not elucidated in detail. Interactions of cells with TNC may be mediated by members of the integrin family, heterodimers of a2/7/8/9b1 and avb1/3/6 as TNC receptor candidates. 1, 2 In a colon cancer in vitro model, tumor necrosis factor (TNF)-a and transforming growth factor (TGF)-b1 were found to cause upregulation of the b6 subunit and consequent increase of avb6 heterodimers contributing to EMT. 20 Transfection of b6 subunits induced EMT in oral squamous cell carcinoma (SCC) cells with enhanced TNC expression. 21 Furthermore, EMT of oral SCC driven by co-stimulation of epidermal growth factor with TGFb1 is associated with elevated expression of a7 and b1 subunits and extracellular matrix proteins including laminin 332 and TNC. 22 Upregulated expression of avb3 is also observed in TGF-b-induced EMT in murine mammary epithelial cells. 23 Moreover, colon cancer cells transfected with a9b1 display an EMT phenotype, 24 and pancreatic cancer cells plated on collagen I show EMT-like change mediated through integrin a2b1. 25 In the present study using MCF-7 cells, we therefore investigated the contributions of multiple integrin receptors, examining expression and alteration during EMT of integrin subunits forming TNC receptors by quantitative PCR (qPCR) and western blotting, in addition to localization by immunofluorescence as well as affinity binding to immobilized TNC and effects of neutralizing antibodies. Subunit expression in human breast cancer tissues was also explored by immunohistochemistry.
RESULTS

Detection of integrin receptors for TNC expressed in MCF-7 cells
Integrins reported as TNC receptors include a2/7/8/9/v and b1/3/6 subunits.
1,2 Substantial mRNA expression of av, a2, b1, and b6 subunits was validated by qPCR ( Figure 1a ), and these subunits were readily detected ( Figure 2a ) in immunoblot analysis of TGFb1/TNC-treated MCF-7 cells. Compared with the C t value for GAPDH, the values for integrin a7/8/9 and b3 subunits were extremely high, indicating insignificant expression in the treated cells. On immunoblotting, integrin b5 subunit was also detected as a positive control in this study, whereas integrin b3 was hardly present, in line with the qPCR findings.
TNC and TGF-b1 treatments increase av and b6 expression A significant increase of av mRNA is observed with the combined treatment, whereas TGF-b1 treatment also showed a similar tendency but without statistical significance (Figure 1b) . Expression of b6 mRNA after TGF-b1 and combined TGF-b1/TNC treatments was significantly increased to 410 times the control value, whereas expression of a2 and b1 was not altered. Immunoblotting demonstrated that protein amounts of av subunits were significantly elevated by TNC and TGF-b1/TNC treatments ( Figure 2b ). The b6 amount was also significantly increased after TNC treatment and more prominently with TGF-b1/TNC, whereas it was lower in TGF-b1 treated cells, but not significantly. Elevated expression of b6 protein after the combined treatments was also noted in T-47D breast cancer cells (Supplementary Figure 1) . The amount of a2 was slightly but significantly increased in TGF-b1-and TGF-b1/TNC-treated cells. The b1 amount was not different among the treatments. Although TGF-b1 upregulated mRNA expression of av and b6 subunits, increases of the protein amounts were not significant. In contrast, TNC treatment did not evidently affect the mRNA expression, but contents of both proteins were significantly increased. TGF-b1/ TNC-treated cells showed marked upregulation at both mRNA and protein levels. TNC addition with or without TGF-b1, but not TGFb1 alone, to the medium induces EMT-like change of MCF-7 cells, this phenotype change being previously characterized in detail. 18 Integrin avb6 heterodimers are recruited to focal adhesions by TNC treatment Immunofluorescence of av subunits in control cells showed patchy staining of bottom surfaces of cell clusters with tiny focal adhesions at the cell peripheries. After TNC and TGF-b1/TNC treatments, the staining was intensely positive in larger adhesion plaques of spreading cells. Immunofluorescence of b6 demonstrated bright fluorescence in adhesion plaques of TNC-and TGFb1/TNC-treated cells but not in control cells (Figure 3a ) or cells treated with TGF-b1 alone (data not shown). Focal adhesions positive for b6 were observed more frequently in TGF-b1/TNCtreated cells than in TNC-treated ones, and colocalized in a part with av-positive plaques (Figure 3b , arrows). Integrin b5 was observed in focal adhesions in accordance with integrin av in all treated cells (Figure 3a) . Plaques positive for b3 were barely detectable. Immunoprecipitation showed increasing b6 contents of integrin heterodimers co-precipitating with the av subunit in TNC-treated cells and, more remarkably, in TGF-b1/TNC-treated ones (Figure 3c ). Upregulated b6 protein may be recruited to focal adhesions as avb6. Figure 1 . Messenger RNA expression of TNC receptors of MCF-7 cells after TGF-b and TNC treatments. (a) mRNA was extracted from cells co-stimulated with TNC (10 mg/ml) and TGF-b1 (5 ng/ml) for synthesis of cDNA and performance of real-time PCR determining the cycle threshold (C t ) values for each subunit. Differences in C t values of TNC receptor mRNAs from that of GAPDH mRNA in TGF-b1/TNC-treated cells are shown using qPCR. C t values of a7/8/9 and b3 integrin subunits were very high, indicating only limited expression. Calibration curves were obtained using each target gene in the samples. (b) Changes of receptor mRNA expression for av/2 and b1/6 after treatment with TGF-b1 and/ or TNC. The results were normalized to GAPDH expression. Integrin av showed significant increase after TGF-b1/TNC treatment and b6 was dramatically increased after TGF-b1 addition, with or without TNC (mean ± s.d.; *Po0.05, ***Po0.001). . While TNC addition significantly increased b6 amounts, TGF-b1/TNC did so more dramatically. The integrin a2 subunit showed slight but significant increase after TGF-b1 treatment (mean±s.d.; *Po0.05, **Po0.01, ***Po0.001). As a control, the b5 was not altered by any of the treatments. Integrin avb1 heterodimers are recruited to focal adhesions by TNC treatment Integrin b1 subunits form heterodimers with av. To detect b1 subunits in focal adhesions, we employed P4G11 antibodies that react with the Ca 2 þ -dependent epitope and activate cell adhesion to extracellular matrix, 26 suggesting recognition of an active form of b1 subunit. In the control case, immunofluorescence using P4G11 revealed small tiny adhesion plaques around cell clusters that were negative for av ( Figure 4d , arrow heads). In TNC-and TGF-b1/TNC-treated cells, P4G11 labeled some portion of av-positive adhesion plaques (Figure 4d , arrows). On immunoprecipitation of cell lysates with P5D2 anti-b1 antibodies, almost equal amounts of a2 were co-precipitated with or without TNC treatment. In contrast, the av contents precipitated with b1 were clearly elevated after TNC and TGF-b1/TNC treatments (Figure 4e ), indicating increasing avb1 heterodimers and their mobilization to focal adhesions after TNC treatment.
Phosphorylation of FAK at Y925 (pY925) has been reported to be a major event in EMT of colon cancer cells. 19 FAK pY925 labeling was here partially colocalized in focal adhesions with av, Figure 2) , suggesting the presence of a signaling pathway for EMT mediated through these integrins.
Neutralizing antibodies inhibit TNC-induced EMT-like change Effects of neutralizing antibodies against integrins on EMT-like change were examined in TNC-treated cells. With TNC treatment alone, addition of the neutralizing anti-av antibody (AV1) blocked the change (Figure 5a ). In the case of treatment with anti-b1 antibody P5D2, the change was also inhibited. In contrast, neutralization antibodies against avb6 (10D5) or a2 (P1E6) did not block EMT. More extensive EMT change was observed with the combination of TGF-b1 and TNC than with TNC alone. In TGF-b1/ TNC-treated cells, AV1 treatment also inhibited the change; however, P1E6, P5D2 or 10D5 alone did not ( Figure 5b ). Next, we tried combined treatment of 10D5 with P1E6 or P5D2. The EMT-like change was abrogated by the combination of 10D5 with P5D2, but not with P1E6 ( Figure 5c ). Cellular signaling for EMT change in TGF-b1/TNC-treated cells could be independently mediated by two types of integrin heterodimers, avb6 and, possibly, avb1.
Integrin avb6 and avb1, but not a2b1, bind to TNC We confirmed binding of avb6 and avb1 integrins to TNC immobilized on agarose beads. Several biotinylated protein bands were seen between 75 and 150 KDa in EDTA extracts (Figure 6a ). By immunoblotting, integrin subunits of b1, b6 and av were detected. Amounts of these subunits bound to TNC were increased in TGF-b/TNC-treated cells, compared with the control case ( Figure 6b ). Integrin a2 subunits were recognized in the lysates, but not in the EDTA extracts. As av is the exclusive partner of b6, it could be confirmed that avb6 binds to TNC. To clarify a heterodimeric partner of b1, we tried addition of anti-b1 antibody in the binding assay. Addition of neutralizing antibodies P5D2 and/or 10D5 significantly decreased av subunit bound to TNCconjugated beads (Figure 6c ), indicating binding of avb1 and avb6 heterodimers to TNC in a divalent cation-dependent manner.
Integrin subunits are expressed in human breast cancer tissues Immunolabelling of the av subunit was mainly found in luminal surfaces of tubular structures in large solid cancer clusters in breast cancer tissues (arrows in av of Figure 7a ), while membrane surfaces were positive in scattered cancer cells. Labeling of the b6 Integrin avb1/6 binding to TNC induces EMT D Katoh et al subunit was generally faint in the cytoplasm of clustered cells. In contrast, densely labeled cells, primarily cytoplasmic and partially membranous, were frequently observed in areas of the scattered pattern (arrows in b6 of Figure 7b ). Positive b6 labeling was significantly more frequent in scattered than solid areas (Po0.0001; Table 1 ), and in stroma with dense TNC deposition (Po0.0001; Table 2 ). Immunostaining of both a2 and b1 was often evident in intercellular contacts between cancer cells in large clustered nests (arrows in a2 and b1 of Figure 7a ), as well as in intraductal non-invasive components of cancers (not shown).
DISCUSSION
The present analysis of mRNA expression of integrin subunits of av/2/7/8/9 and b1/3/6 allowed selection of av/2 and b1/6 as candidate subunits for TNC receptors in MCF-7 cells (Figure 1a) . Expression of these subunits could also be successfully detected at the protein level by immunoblotting, whereas in the a7/8/9 and b3 cases it was very low with high C t values. Indeed, the b3 protein was hardly detected in immunoblotting and positive adhesion plaques were essentially not observed. This is in line with a recent study showing no a9 protein on flow cytometry of MCF-7 cells, expression being closely related to the basal-like subtype of breast cancer cell. 27 MCF-7 cells are luminal subtype. 28 A recent study showed that a9b1 expression of colon cancer cells induces phenotypic changes consistent with EMT. 24 Most breast cancer cell lines of basal-like subtype exhibit a mesenchymal phenotype, 28 which may be associated with specific integrin expression including a9b1.
Integrin avb6 is not normally expressed in the epithelium but it is induced during wound repair, 29, 30 accompanied by TNC expression. 31 It is also highly upregulated in a variety of neoplastic epithelial cells, [32] [33] [34] including breast cancer. 35 Furthermore, expression is indicative of a poor outcome of patients with colon cancers 20 and more frequent liver metastases. 36 It is also associated with a poorer patient outcome in early-stage gastric cancers. 37 Moreover, preferential expression is observed in invasion fronts of oral SCCs 38 and in small cell clusters of colon cancers invading the stroma. 20 Our b6 immunohistochemistry also showed scattered cancer cells to be more frequently positive than those forming solid masses ( Figure 7 and Table 1 ).
Overexpression of b6 by transfection induces EMT with enhanced TNC expression in oral cancer cells. 21 Another EMT model with colon cancer cells exposed to TNF-a and TGF-b1 demonstrate transcriptional upregulation of the b6 subunit and consequent induction of avb6 expression engaged in the phenotypic change. 20 Colonic cells after TGF-b1 treatment show greater than three-fold increase in b6 expression in both the mRNA level and flow cytometry. In the present study, b6 mRNA was also dramatically upregulated by TGF-b1 (Figure 1b ), but the protein amount was prominently increased only by co-stimulation with TNC (Figure 2b ), being associated with EMT change. Similar results were also seen in TNC treatment of another breast cancer cells T-47D (Supplementary Figure 1) . TGF-b1 alone did not increase b6 protein in immunoblotting, whereas protein expression was elevated by addition of TNC as a ligand. Regarding mRNA levels, our observations for MCF-7 cells are compatible with those for colon cancer, but inconsistency was noted with protein levels. This study showed colocalization of av and b6 subunits in focal adhesions and dramatic increase of co-precipitated avb6 heterodimers after TGF-b1/TNC treatment (Figures 3b and c) . Further, we could directly demonstrate avb6 binding to TNC ( Figure 6 ). As MCF-7 itself does not produce TNC even after TGF-b1 stimulation, 18 exogenous application of TNC may be necessary to stabilize avb6 proteins by binding as a ligand. TGF-b is generally an inducer of TNC synthesis in both epithelial and mesenchymal cells. Expression of TNC in colon cancer cells after TGF-b1 addition therefore should be examined.
Immunohistochemistry of oral SCC demonstrated b6 labeling at the epithelial-connective tissue interfaces, associated with TNC staining. 39 In late stages of oral mucosal healing, b6 expression in the basal cells temporarily and spatially coincides with TNC expression in epithelial cells and granulation tissue beneath the repairing epithelium. 31 In bullous keratopathy corneas, b6 expression specifically correlates with the deposition of subepithelial TNC, more than with fibronectin or vitronectin, other avb6 ligands. 40 We also demonstrated b6-positive cancer cells to be more frequent in TNC-positive areas in breast cancer tissues (Table 2 ). Our observation of stabilization of b6 protein by TNC could account for the close association between TNC and avb6 integrin. In addition, as avb6 integrin can activate latent TGF-b, 41 ,42 release of TGF-b from the latency-associated protein may stimulate expression of both TNC and b6 subunits by epithelial (cancer) cells and of TNC by adjacent stromal fibroblasts, forming a loop of amplified TGF-b signals.
Neutralizing antibodies 10D5 against avb6 and P5D2 for b1 cooperated in inhibiting EMT under TGF-b1/TNC treatment (Figure 5c ). The experiments clarified that integrins actually contribute to EMT signaling after TGF-b1/TNC treatment. Integrin avb6 binds to TNC and mediates the signaling, but another integrin containing b1 independently acts in the EMT induction. We speculated that avb1 integrin as well as avb6 is conducive for TNC-induced EMT. Integrin avb1 is an RGD-dependent receptor for fibronectin, vitronectin 43 and osteopontin. 44 It has been suggested that TNC is also a ligand, albeit with limited direct evidence. Migration of oligodendrocyte precursors on astroglial matrices rich in TNC is inhibited by anti-avb1 antibodies. 45 Adhesion of glioma U251.3 cells to TNC was found to be completely blocked by combined treatment with av and b1 antibodies. 46 Epithelial cells also express avb1 heterodimers. 47 In this study, av subunits co-precipitated by b1 antibodies were increased in TNC-and TGF-b1/TNC-treated cells, colocalizing in focal adhesions (Figures 4d and e) . EMT induced by TNC alone was inhibited by P5D2 or AV1 alone (Figure 5a) . Furthermore, addition of the neutralizing antibody reduced av subunits in the binding assay to TNC, supporting heterodimer formation of the subunits binding to TNC (Figure 6c ). These findings provide the first direct evidence that avb1 heterodimers act as a receptor for TNC, constituting a signaling pathway to evoke EMT.
Integrin a2b1 induces collagen-I mediated EMT-like change of pancreatic cancer cells through FAK phosphorylation, cooperating with DDR1. 25 Integrin a2b1 also binds to TNC, and contributes to attachment and spreading on endothelial cells. 48 This integrin is also responsible for cell adhesion and migration of cancer cells on Integrin avb1/6 binding to TNC induces EMT D Katoh et al TNC. 49 In both these earlier experiments, the neutralizing anti-a2 antibody P1E6 inhibited TNC functions. Here, P1E6 did not block EMT change ( Figure 6 ) and affinity binding of a2 for TNC could not be observed (Figure 5 ), indicating no involvement of a2b1, at least, in induction of EMT in MCF-7 cells.
We have shown clearly that avb1 and avb6 integrins can independently participate in TNC-induced EMT-like change. Additional exposure to avb6 with avb1 may be responsible for the stronger phenotypic change of TGF-b1/TNC-treated cells than with TNC alone. We can conclude that these integrins transduce EMT signals from the TNC-rich environment of cancer tissues. Integrin avb6 may promote migration, generate signals for proliferation and protection from anoikis, activate latent TGF-bs and upregulate matrix metalloproteinase expression. [32] [33] [34] The interaction of avb6 with TNC may yield signals for more malignant behavior of cancer cells including EMT. Further investigations are warranted to clarify their interrelationships in a variety of pathological states. In addition, functions of the avb1 integrin in cancer progression, much less explored than avb6, are clearly of interest.
MATERIALS AND METHODS Antibodies
Antibodies used in this study are summarized in Table 3 .
Cell culture, EMT induction and blocking by antibodies MCF-7 cells and T-47D were cultured as previously described. 18 After seeding at 5 Â 10 4 cells per well in 12-well plates (BD Falcon, Franklin Lakes, NJ, USA), 10 mg/ml of TNC purified from conditioned medium of U-251MG 8 was added to the medium. After overnight incubation, 5 ng/ml of TGF-b1 (Roche Diagnostics, Mannheim, Germany) was added and the cells were cultured for a further 48 h. Induction of EMT-like change of T-47D was assessed as previously described. 18 Neutralizing antibodies (5 mg/ml) for avb6, a2 and b1 were added to the medium when the cells were plated. The anti-av antibody was added at 1:40 after overnight incubation. As a negative control, protein A-purified monoclonal antibody against a paramyxovirus protein (IgG 1 k) was used.
Quantitative reverse-transcription PCR Expression of mRNAs for integrin subunits av/2/7/8/9 and b1/b3/6 was quantified by qPCR. Total RNA was extracted using the ISOGEN reagent (Nippon Gene, Tokyo, Japan). Total RNA (1 mg) was reverse-transcribed using a cDNA synthesis kit (Roche Diagnostics) with anchored-oligo (dT) 18 primers. Quantitative PCR was performed using a LightCycler real-time PCR instrument and an SYBR Green I Master kit (Roche Diagnostics). QuantiTect primers for the subunits and GAPDH were purchased from Qiagen (Valencia, CA, USA). The reactions were performed at 95 1C for 10 min to activate the polymerase, followed by 40 cycles at 95 1C/5 s, 55 1C/10 s and 72 1C/20 s. The specificity of the PCR reactions was confirmed with a heat dissociation protocol (from 60-95 1C). The PCR cycle threshold (C t ) values were determined with the second derivative maximum method using LightCycler Software. Quantitative analyses of expression changes of integrin mRNAs after the treatments were performed at least in triplicate.
Immunoblotting
Cells were lysed using a lysis buffer (1% SDS, 50 mM Tris-HCl buffer, pH 6.8).
The amount of protein in each extract was evaluated by bicinchoninic acid assay (BCA, Pierce, Rockford, IL, USA). Equal amounts of total protein were mixed with Laemmli's sample buffer without 2-mercaptoethanol and electrophoresed on 5-20% polyacrylamide gradient gels. The proteins were electrically transferred to Immobilon membranes (Millipore, Billerica, MA, USA), and labeled with primary antibodies against integrin av/2, b1/3/5/6 and a-tubulin as an intrinsic control, followed by exposure to peroxidaselabeled anti-mouse IgG (3000-5000-fold diluted; Bio-Rad, Hercules, CA, USA) or anti-rabbit IgG (2000-fold diluted; Sigma-Aldrich, St Louis, MO, USA) and visualization with ECL Plus (GE Healthcare, Waukesha, WI, USA). First antibodies were used at 1000-3000-fold dilutions. Band intensities were quantified using Image J and the values were normalized to intensities of a-tubulin bands. All quantitative analyses were performed at least in triplicate.
Immunofluorescence MCF-7 cells were grown on cover glasses and fixed in 2% paraformaldehyde/PBS with 0.2% Triton X-100 for 10 min. After treatment with 10% normal goat serum, they were exposed to primary antibodies against E-cadherin, b-catenin, av/2 and b1/3/5/6. Subsequently, the cells were treated with appropriate secondary antibodies, fluorescein-labeled goat anti-mouse IgG or anti-rabbit IgG (200-fold diluted; MBL, Nagoya, Japan). For double immunofluorescence, rhodamine-labeled goat anti-mouse IgG (Tago, Burlingame, CA, USA) was used. For P4G11, 1 mM CaCl 2 was included in all solutions. 26 Observation was performed under an epifluorescence microscope with appropriate filter sets and a 40 Â or 60 Â objective lens (Olympus, Tokyo, Japan), and photographs were taken using a cooled CCD camera.
Immunoprecipitation
Cells were lysed in ice-cold lysis buffer, 1% Nonidet P-40, 20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM CaCl 2 and 1 mM MgCl 2 with protease inhibitors (complete mini EDTA-free, Roche Diagnostics). The lysates were centrifuged at 15 000 Â g for 20 min and supernatants were pre-cleared with protein G beads (Sigma-Aldrich) for 30 min, then incubated with antibodies 
Abbreviations: M, mouse; R, rabbit.
Integrin avb1/6 binding to TNC induces EMT D Katoh et al against av, a2 and b1, or mouse IgG as a negative control, at 4 1C for 1 h. Complexes were precipitated with protein G beads for 2 h. The beads were then washed three times with the lysis buffer and boiled with sample buffer. The samples were subjected to immunoblotting, employing primary antibodies of rabbit origin. Representative data are shown from at least three independent experiments that yielded similar results.
Binding of integrins to TNC
Cell surface proteins were biotinylated by incubating the cells with 0.5 mg/ 0.5 ml of sulfo-NHS-biotin (Pierce) in PBS at 4 1C for 1 h. After several washes, biotinylated cells were lysed with 0.5 ml of extraction buffer (50 mM Tris-HCl, pH 7.6, 50 mM NaCl, 100 mM n-octyl-b -D-glucoside (Dotite, Kumamoto, Japan), 1 mM MgCl 2 , 2mM MnCl 2 , plus protease inhibitor cocktail) for 20 min at 4 1C. Cell debris was removed by centrifugation, and the supernatants were pre-cleared by incubation for 1 h with agarose beads. Purified TNC (0.5 mg) was coupled to 1 ml of NHS-activated agarose (Pierce). TNC-conjugated beads (100 ml) were added into the pre-cleared supernatants, and the slurry was incubated with vigorous agitation at 4 1C overnight. The beads were subsequently extensively washed with extraction buffer, and sequentially with the buffer containing 0.2 M NaCl twice. The binding proteins were eluted by 100 ml of the extraction buffer without divalent cations supplemented with 20 mM EDTA. Samples were analyzed by staining with peroxidase-conjugated streptavidin (2000-fold diluted, GE Healthcare) or immunoblotting. Neutralizing antibody P5D2 or 10D5 (1.5 mg) was added into the pre-cleared supernatants, followed by 1-h incubation and then addition of TNC beads.
Immunohistochemistry
Immunohistochemical analysis was performed on 35 cases of fully invasive ductal carcinoma of the breast using archival samples for pathological diagnoses that had been fixed in formalin and routinely processed for embedding in paraffin. Use of the samples was approved by written informed consent from the patients under a protocol authorized by the ethical committee of our university. The same samples and immunohistochemical techniques had been used in our previous paper. 18 Sections were treated with Super Block solution (Scytek Laboratories, Logan, UT, USA) before incubation with primary antibodies against TNC, av/2, b1/6 and E-cadherin overnight. All primary antibodies were used at a concentration of 0.5 mg/ml or a 1000-fold dilution. After being washed, sections were treated with a commercially available polyvalent LSAB kit (Scytek), followed by color development with 3,3 0 -diaminobenzidine/H 2 O 2 solution. The invasive patterns of ductal carcinomas at the peripheral margins of the tumours were classified into two groups: solid and scattered. A maximum of three representative areas of each type were selected in each breast cancer specimen, and immunoreactivity was assessed in 63 solid-and 84 scattered-type areas. Immunolabelling of b6 subunits in cancer cells stronger than that in normal epithelium was defined as positive. The relation between TNC and b6 positivity was examined in the same fields of adjacent serial sections.
Statistical analyses
Results are presented as means ± s.d's. Statistical analysis was performed by one-way analysis of variance with the Bonferroni means comparison test. Differences in TNC and b6 staining with reference to histological patterns and between TNC and b6 labeling were assessed by Fisher's exact test. Po0.05 was considered statistically significant. ABBREVIATIONS EMT, epithelial-mesenchymal transition; FAK, focal adhesion kinase; LSAB, labeled streptavidin biotin; NHS, N-hydroxysuccinimide; qPCR, quantitative PCR; SCC, squamous cell carcinoma; TGF, transforming growth factor; TNC, tenascin-C; TNF, tumor necrosis factor
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